We next examined the specificity of GroA treatment toward cancer cells, and found that it reduces the viability of SKBR3 human breast cancer cell lines, but has virtually no effect in the non-cancerous, human breast tissue cell line, MCF10A (Fig. 3b, right). This evidence concerns the gene CXCL1 and breast carcinoma.